logo BDSP

Base documentaire

  1. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City : Project ACHIEVE.

    Article - En anglais


    Candidate populations for HIV-1 vaccine efficacy trials need to be at high risk of infection, adhere to study protocols and be willing to participate.

    The goal of Project ACHIEVE is to collect baseline data needed in order to prepare for vaccine efficacy trials among gay/bisexual men in New York City.

    Design and methods 

    HIV-1 antibody-negative men were recruited into a cohort study with follow-up visits every 3 months (n=622).

    Frequency of high-risk behaviors and incidence of HIV-1 seroconversion were measured.


    Of 544 men reporting having had at least one partner in the previous 3 months who was HIV-1 antibody-positive or of unknown status at baseline, 49% reported receptive anal sex encounters.

    Thirty-two per cent of these men reported the highest risk behavior, unprotected receptive anal sex.

    The follow-up rate at 12 months was 81%. The incidence rate of infection was 2.9 per 100 person-years (95% confidence interval : 1.7,4.9).

    During follow-up, declines were observed in the proportion of men with an HIV-1 antibody-positive partner and the proportion reporting unprotected receptive or insertive anal sex.

    HIV-1 infection rates declined from 4.3 per 100 person-years in the first 6 months to 1.6 per 100 person-years by the 12-month visit.


    Gay/bisexual men in New York City are still placing themselves at risk of HIV-1 infection and may be a suitable population for future vaccine trials. (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Homosexualité, Bisexualité, Essai clinique, Immunoprophylaxie, Vaccin, Prévention, Homme, New York, Etats Unis, Amérique du Nord, Amérique, Programme sanitaire, Immunopathologie, Immunodéficit

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Homosexuality, Bisexuality, Clinical trial, Immunoprophylaxis, Vaccine, Prevention, Human, New York, United States, North America, America, Sanitary program, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0008799

    Code Inist : 002B06D01. Création : 21/05/1997.